Riskpilot← Back to searchSign inGet full accessSavara ApS
APSActiveCVR 37643459Amaliegade 10Research and experimental development on natural sciences and engineering · NACE 7210Est. 20167 employees
Revenue 2024
DKK -3,4M
+55% vs 2023
EBITDA margin
100.0%
-55% vs 2023
Equity ratio
-24.9%
Financial strength
Net profit 2024
DKK 229,9M
+71277% vs 2023
| Revenue | DKK -3,4M | +55% |
| EBITDA | DKK -3,4M | -55% |
| Net profit | DKK 229,9M | +71277% |
| Total assets | DKK 1,1B | +113% |
| Equity | DKK -276,4M | +45% |
| Employees | 7 | — |
Legal name
Savara ApS
CVR number
37643459
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
27. april 2016
Share capital
DKK 50.000
Employees
7 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af én direktør.
Company purpose
Selskabets formål er medicinsk forskning og udvikling samt produktion og salg af farmaceutiske produkter samt virksomhed, som har forbindelse hermed.
Address
Amaliegade 10
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 697 | 6.533 | 9.928 | 20.517 | 29.197 | 13.495 | -2.228 | -2.194 | -3.393 |
| Staff expenses | -3.534 | -9.272 | -12.938 | -27.122 | -38.208 | -19.003 | -40 | -0 | -0 |
| EBITDA | -2.837 | -2.739 | -3.010 | -6.605 | -9.011 | -5.508 | -2.188 | -2.194 | -3.393 |
| Depreciation & amort. | -0 | -0 | -0 | -152 | -205 | -516 | -0 | -0 | -0 |
| EBIT | -2.837 | -2.739 | -3.010 | -6.757 | -9.216 | -6.024 | -2.188 | -2.194 | -3.393 |
| Net financials | -559 | -7.991 | -18.075 | -9.804 | 46.754 | -57.185 | -434.392 | 12.529 | 247.194 |
| Profit before tax | -3.396 | 5.252 | -21.085 | -16.561 | 37.538 | -63.209 | -436.580 | 10.335 | 243.801 |
| Tax | -568 | -19 | 165 | -0 | 4.312 | -0 | 4.091 | 10.658 | 13.900 |
| Net profit | -2.828 | 5.271 | -21.250 | -16.561 | 33.226 | -63.209 | -440.671 | -323 | 229.901 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 105.197 | 183.181 | 295.056 | 445.019 | 573.998 | 682.467 | 395.503 | 519.553 | 1.108.078 |
| Equity | -2.778 | 2.493 | -18.757 | -35.318 | -2.092 | -65.301 | -505.972 | -506.296 | -276.395 |
| Long-term debt | 0 | 0 | 0 | 1.045 | 2.203 | 2.541 | 2.273 | 2.690 | 2.592 |
| Short-term debt | 107.975 | 180.688 | 313.813 | 479.292 | 573.887 | 745.227 | 899.202 | 1.023.159 | 1.381.881 |
| Total debt | 107.975 | 180.688 | 313.813 | 480.337 | 576.090 | 747.768 | 901.475 | 1.025.849 | 1.384.473 |
EBITDA margin
-339300000.0%
This company
15.8%
Market median
-2147468454% vs market
20162024
Equity ratio
-24.9%
This company
38.2%
Market median
-165% vs market
20162024
Return on equity
22990100000.0%
This company
18.4%
Market median
+124946195552% vs market
20162024
Net profit margin
22990100000.0%
This company
8.1%
Market median
+283828394962% vs market
20162024
Asset turnover
-0.00×
This company
1.12×
Market median
-100% vs market
20162024
Debt / equity
5.01×
This company
0.62×
Market median
-708% vs market
20162024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-04-27 – 2016-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
DL Management | Management | 2017 | — | — |
RN Management | Management | 2016 | — | — |
MR Management | Management | 2020 | — | — |
BK Management | Management | 2016 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 2016 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Savara ApS 
PHARMAORIGIN ApSBoard members of Savara ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| David Lee Lowrance | Management | 0 companies |
| Robert Norman Neville | Management | 0 companies |
| Matthew Rudolph Pauls | Management | 0 companies |
| Bent Kemplar | Management | 0 companies |